LNP-mRNA Vaccine Encoding C. psittaci MOMP Induces Protection in Mice

Study Background and Research Question

Chlamydia psittaci is a zoonotic pathogen capable of causing psittacosis, a severe respiratory illness in humans and significant morbidity in avian and livestock populations. Traditional vaccine development against C. psittaci has faced barriers due to its strict intracellular lifecycle and capacity for subclinical or recrudescent infections. With the increasing incidence of chlamydial infections and limitations of antibiotic therapy, there is a pressing need for innovative vaccine platforms that can induce robust and durable immunity (Wang et al., 2025).

This study addresses a pivotal research question: Can an mRNA vaccine encoding the major outer membrane protein (MOMP) of C. psittaci, delivered via lipid nanoparticles, stimulate effective immune protection in a murine model?

Key Innovation from the Reference Study

The principal innovation lies in the application of lipid nanoparticle (LNP)-delivered, in vitro transcribed, non-replicating mRNA encoding MOMP of C. psittaci. The study leverages chemical modifications to the mRNA—including incorporation of nucleoside analogs—to enhance stability and reduce innate immune activation, a strategy previously shown to boost protein translation and vaccine tolerability. This approach enables the efficient expression of antigenic protein in host cells, aiming to simulate natural infection and elicit both humoral and cellular immune responses (Wang et al., 2025).

Methods and Experimental Design Insights

The investigators synthesized mRNA encoding the optimized MOMP sequence using an in vitro transcription system, incorporating modified nucleotides for immune evasion and stability. The resulting mRNA was encapsulated in LNPs, which were characterized by size, morphology, and cytotoxicity. Key experimental steps included:

• Validation of mRNA-mediated MOMP expression in HeLa cells (via western blot analysis).
• Immunization of BALB/c mice with the LNP-mRNA construct, followed by challenge with C. psittaci.
• Assessment of pulmonary bacterial load, cytokine profiles (IFN-γ, TNF-α, IL-6), and histopathological changes post-infection.
• Evaluation of immune responses using indirect immunofluorescence and quantification of pathogen shedding.

The workflow illustrates the effective translation of in vitro transcribed, chemically modified mRNA into a preclinical vaccine format, integrating nucleoside modification principles recognized for immune response reduction (internal article).

Protocol Parameters

• Antigen Selection: Use of optimized MOMP coding region for immunogenicity.
• In vitro mRNA synthesis: Incorporate nucleoside modifications (e.g., pseudouridine) to enhance translation and reduce innate immune sensing.
• LNP Formulation: Prepare LNPs using established microfluidic mixing, ensuring particle uniformity and low cytotoxicity.
• Immunization: Administer LNP-mRNA via intramuscular injection; use age- and sex-matched BALB/c mice for consistency.
• Challenge Model: Infect mice with defined inoculum of C. psittaci post-vaccination for efficacy assessment.
• Outcome Measures: Quantify pulmonary bacterial load, cytokine production, and histopathological scores post-challenge.

Core Findings and Why They Matter

The LNP-mRNA vaccine expressing C. psittaci MOMP demonstrated several significant outcomes (Wang et al., 2025):

• Robust Immunogenicity: Vaccinated mice developed strong humoral and cellular immune responses, as indicated by antibody titers and functional T cell assays.
• Reduction in Pathogen Load: Immunized animals exhibited markedly lower pulmonary C. psittaci burden compared to controls, supported by quantitative PCR and immunofluorescence.
• Attenuation of Inflammatory Response: Levels of IFN-γ, TNF-α, and IL-6 in lung tissue were significantly decreased, suggesting reduced immunopathology.
• Histopathological Protection: Lung sections from vaccinated mice showed reduced inflammatory infiltration and tissue damage.

These findings confirm that LNP-mRNA vaccines, when encoding optimized antigens and incorporating immune-evasive nucleotide modifications, can provide effective protection against respiratory bacterial pathogens. This supports the broader application of mRNA vaccine technology in both zoonotic and emerging infectious diseases, aligning with recent advances in immune-evasive mRNA synthesis and RNA vaccine development.

Comparison with Existing Internal Articles

Several internal resources contextualize the significance of this study. For example, a recent summary underscores the synergy between in vitro transcription of modified mRNA and LNP delivery for respiratory vaccine applications. The HyperScribe All in One mRNA Synthesis Kit Plus 1 is highlighted for its streamlined workflow in generating ARCA-capped, polyadenylated, and chemically modified mRNA, which parallels the synthesis requirements in the reference study. Mechanistic reviews (internal review) further discuss how 5mCTP and ψUTP modifications reduce host immune activation, a principle that underpins successful RNA vaccine development and was leveraged in the current research.

This cross-reference demonstrates that the innovations in the reference study are built on established advances in immune response reduction by modified nucleotides and in vitro translation of modified mRNA, as explored by both academic and translational research communities.

Limitations and Transferability

While promising, the study's findings must be interpreted with certain limitations in mind:

• Species Specificity: Protective efficacy was demonstrated in BALB/c mice, and immunological responses may not fully extrapolate to other models or humans.
• Pathogen Diversity: The vaccine targeted a single, optimized antigen (MOMP) from C. psittaci; antigenic variation among Chlamydia species could limit cross-protection.
• Manufacturability: While scalable, LNP-mRNA vaccine production requires tight control of mRNA quality, capping, and nucleotide modification—factors directly addressed in synthesis kit design but still sensitive to protocol variation.
• Duration of Protection: The study primarily assessed short-term immune outcomes; longer-term durability and memory responses remain to be established.

Why this cross-domain matters, maturity, and limitations

This research bridges the domains of zoonotic infectious disease control and advanced RNA vaccine technology. The demonstrated protection against C. psittaci in mice suggests feasibility for targeting other respiratory pathogens, supporting the rationale for pan-respiratory vaccine platforms. However, translation to field or clinical use will require further validation of immune response durability, safety, and performance across diverse hosts and epidemiological settings.

Research Support Resources

For laboratories aiming to replicate or extend these workflows, the HyperScribe™ All in One mRNA Synthesis Kit Plus 1 (ARCA, 5mCTP, ψUTP, T7, poly(A)) (SKU K1064) from APExBIO offers a comprehensive solution for the in vitro synthesis of ARCA-capped, polyadenylated, and chemically modified mRNAs. This kit is optimized for workflows requiring immune response reduction and efficient in vitro translation, as exemplified in the referenced mRNA vaccine study. Its integrated protocol supports high-yield RNA production suitable for applications ranging from RNA vaccine development to RNA interference experiments and functional studies of mRNA stability and translation.